The Alzheimer's Drug With a 25% Brain Bleed Risk - Dr. David Perlmutter | TUH #306

Episode Overview

• Neurologist Dr. David Perlmutter joins host Gary Brecka to explain how systemic metabolic dysfunction and inflammation drive the brain's innate immune cells (microglia) to cause cognitive decline and Alzheimer's disease—which is currently the third leading cause of adult death in America and affects 7.6 million Americans.
• The conversation reframes Alzheimer's not as a sudden affliction of old age, but as the late-stage manifestation of "Pre-Alzheimer's"—a metabolic condition brewing for 20 to 40 years prior, heavily driven by undiagnosed pre-diabetes and insulin resistance.
• Perlmutter challenges the pharmaceutical industry's beta-amyloid hypothesis, contrasting the severe risks and "trivial" benefits of anti-amyloid monoclonal antibody drugs with clinical trials showing that comprehensive lifestyle interventions can halt or reverse cognitive decline.
• The episode provides a detailed scientific roadmap—spanning exercise physiology, sleep glymphatics, genetic polymorphisms (APOE4 and MTHFR), targeted biomarkers, nutritional biochemistry, and emerging therapies—for keeping the brain's immune cells in a protective, supportive state.

Key Concepts

• The Decades-Long Runway of "Pre-Alzheimer's": While clinical cognitive decline typically manifests in a person's 70s and reaches a 40% to 50% risk by age 85, the underlying pathology begins in one's 30s, 40s, and 50s. Perlmutter defines "Pre-Alzheimer's" through metabolic markers: elevated blood sugar, rising fasting insulin, elevated A1C, increasing waist-to-hip ratio, growing belly fat, and rising blood pressure. Because 90% of pre-diabetic Americans are unaware of their status—often dismissed during annual checkups because they haven't crossed into full diabetes, as happened to Brecka's mother for nearly 20 years—millions miss the critical window to prevent a disease that costs the US $360 billion annually.
• Brain Insulin and the Nuance of "Type 3 Diabetes": Perlmutter considers the popular term "Type 3 diabetes" somewhat myopic because insulin does not affect the entire brain equally; it primarily targets the hypothalamus, hippocampus, prefrontal cortex, and olfactory bulb. In the brain, insulin functions as a trophic hormone (similar to BDNF) that nurtures neurons and synapses. Because Alzheimer's involves brain insulin resistance rather than a simple lack of insulin, Perlmutter has mixed feelings about and largely rejects intranasal insulin therapies, comparing them to giving extra insulin to a Type 2 diabetic who already has high insulin, rather than using a ketogenic diet to restore actual insulin sensitivity.
• Immunometabolism and Microglial Polarization (M2 vs. M1): "Immunometabolism" describes how the brain's innate immune cells—microglia—mirror the body's systemic metabolism. In their healthy M2 configuration, microglia act as "brain defenders" that nurture synapses, protect neurons, and maintain the blood-brain barrier. When threatened by metabolic dysfunction or systemic inflammatory cytokines (originating from leaky gut/dysbiosis, periodontal gum disease, or inhaling PM 2.5 from wildfire smoke across 20,000 daily breaths), microglia polarize into their destructive M1 configuration. In this "evil twin" state (which is an innate immune failure rather than a classic antibody-driven autoimmune disease), their mitochondrial function evaporates almost entirely; they switch to inefficient, cancer-like glycolysis to produce ATP, destroy synapses, destabilize the blood-brain barrier, and sever brain connectivity—meaning patients initially lose access to their memories rather than the memories themselves.
• Visualizing Brain Inflammation via PET TSPO Scans: Clinicians and researchers can image activated microglia in living humans using a PET TSPO scan, as TSPO is expressed much more heavily on the mitochondrial membranes of destructive M1 microglia than supportive M2 cells. Perlmutter presents data showing that positive TSPO scans are a shared denominator across a vast spectrum of conditions: Alzheimer's disease, mild cognitive impairment, Parkinson's disease, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), frontotemporal dementia, Lewy body dementia, Huntington's disease, ALS, multiple sclerosis, acute and chronic traumatic brain injury, ischemic stroke, epilepsy, Long COVID, chronic fatigue syndrome, PTSD, bipolar disease, fibromyalgia, and major depressive disorder.
• Genetic Predisposition vs. Destiny (APOE4 and MTHFR): Roughly 25% of the population carries an APOE4 allele, which increases Alzheimer's risk (more strongly in women than in men) by making microglial cells more vulnerable to shifting into the destructive M1 state. However, carrying one or two alleles is a predisposition, not a sentence. Similarly, genetic polymorphisms in the MTHFR gene impair the body's ability to process standard B vitamins, leading to elevated homocysteine—a potent risk factor for both cardiovascular disease and Alzheimer's that can be corrected once the genetic bottleneck is bypassed.
• Muscle as an Endocrine Organ and Mitochondrial Biogenesis: Sarcopenia (muscle loss) is a direct risk factor for metabolic dysfunction and Alzheimer's. Contracting muscle acts as an endocrine gland by secreting myokines, including irisin, which crosses into the brain to stimulate BDNF (brain-derived neurotrophic factor) to grow new neurons and synapses. Muscle activity also releases Interleukin-6 (IL-6), which acts as a beneficial hormetic stressor that activates AMP kinase (AMPK) and the PGC-1alpha pathway—driving mitochondrial biogenesis (creating new mitochondria), clearing out defective mitochondria, and converting standard fat into metabolically favorable brown fat (which gets its brown color from its high density of mitochondria).
• The Failure of the Beta-Amyloid Hypothesis vs. Lifestyle Trials: Perlmutter argues that the beta-amyloid hypothesis should be abandoned, noting that many cognitively intact people have high brain beta-amyloid while many Alzheimer's patients lack significant amyloid. He cites a recent Cochrane analysis of 20,342 individuals across 17 studies (each lasting 18 months) showing that IV anti-amyloid monoclonal antibody drugs offer "trivial" benefits while causing brain hemorrhages, brain swelling, or death in 25% (1 in 4) of patients. Conversely, a 20-week lifestyle trial by Drs. Rudolph Tanzi and Dean Ornish in 51 diagnosed Alzheimer's patients found that a plant-forward diet, exercise, and stress management halted decline or improved cognition in 70% of participants. Furthermore, the 2-year JAMA POINTER study of over 20,000 metabolically compromised older adults (aged 65+, including many APOE4 carriers) showed dramatic cognitive improvements using diet, exercise, stress mitigation, and the BrainHQ app—both in the intensive group (18 meetings/year) and the self-guided group (3 meetings/year). Similarly, the 2024 Lancet Commission reported that addressing 14 modifiable lifestyle factors could reduce dementia incidence by up to 50% (though Perlmutter notes The Lancet omitted diet and rejected his and Dr. Robert Lustig's letter pointing this out).
• Sleep, Glymphatics, and the Acute Impact of Deprivation: Spending a third of life (~8 hours per night) in restorative sleep allows the brain's glymphatic system to clear accumulated metabolic debris, misfolded proteins, glycated proteins, and bacterial breakdown products. Even a single night of non-restorative sleep impairs insulin sensitivity, raises blood sugar, and triggers inflammatory cytokines that push microglia toward the M1 state—though recent research using cognitive testing and fMRI indicates that caffeine can offset some of the acute next-day cognitive dysfunction from a single poor night of sleep.
• Nutritional Biochemistry (Creatine, Vitamin D, and Omega-3s):
• Creatine: While the brain synthesizes its own creatine and systemic creatine crosses the blood-brain barrier only to a limited degree, a very small human trial (n=5) in Alzheimer's patients showed cognitive improvements and increased brain creatine on imaging. Perlmutter admits it is early to be bullish on creatine for Alzheimer's and notes it acts as a phosphate reservoir (phosphocreatine) rather than a direct mitochondrial tonic, and he is not compelled by claims that creatine HCl is superior to monohydrate. Importantly, creatine breaks down into blood creatinine, which frequently causes doctors to misdiagnose supplemented individuals with kidney failure if they do not check BUN or eGFR.
• Vitamin D and Tau: Microglia possess Vitamin D receptors (VDR). A 16-year prospective study following thousands of individuals from their 30s found that higher baseline Vitamin D correlated with lower brain levels of destructive tau protein 16 years later (though Perlmutter caveats this study shows correlation, not strict causation).
• Omega-3s: DHA is a primary structural component of neuronal membranes and synapses, a COX-2 inhibitor, and a stimulator of BDNF. Perlmutter critiques a recent observational study claiming fish oil slightly increased Alzheimer's risk, attributing the finding to reverse causation/selection bias (people experiencing early cognitive decline start taking fish oil) and the use of oxidized, poor-quality fish oil sold in clear plastic bottles.
• The Neurobiology of Social Connection vs. Isolation: Citing Dr. Robert Sapolsky's primate research, Perlmutter and Brecka explain that social isolation elevates cortisol, which directly damages and shrinks the hippocampus and increases all-cause mortality. Conversely, eye-to-eye contact with another human—or even looking into the eyes of a dog—releases oxytocin, which binds directly to receptors on microglial cells and instructs them to remain in their protective M2 configuration.
• Emerging and Experimental Brain Therapies: Research is rapidly advancing on novel ways to rescue microglia and mitochondria:
• Transcranial Red Light Therapy: Penetrates the skull to dissociate nitric oxide from cytochrome c oxidase inside mitochondria, reducing inflammation and supporting microglia (though Perlmutter notes much of the mechanistic proof comes from laboratory animals).
• Foralumab: An intranasal monoclonal antibody being studied at Brigham and Women's Hospital for MS and brain trauma that locks microglia into their supportive M2 state.
• RNS60: An experimental compound by Revalesio consisting of hyper-oxygenated normal saline with oxygen nanobubbles targeting mitochondria; in trials, it extended life by 6 months and preserved speech/respiration in ALS, and halved hospital stays for stroke patients (Perlmutter jokingly says "Busted" when Brecka notes he has personal access to it, though it is not publicly available).
• Cellular & Genetic Interventions: Doctors have successfully harvested healthy mitochondria from leg muscles to transplant into the hearts of children post-surgery to help them survive and come off ECMO; CRISPR-edited stem cells have been turned into healthy M2 microglia to arrest a fatal genetic form of ALS (ALSD) in humans; and intranasal exosomes derived from human microglia-like cells have reduced beta-amyloid and preserved cognition in Alzheimer's mouse models.

Quotes

• At 0:00:00 - "Alzheimer's is an almost uniformly fatal condition. The third leading cause of death in adults in America." - framing the severity and mortality rate of Alzheimer's disease in the United States.
• At 0:05:05 - "When you begin to have these cognitive issues, forgetting why you walked into the room, the Wi-Fi code, the grandchildren's names, whatever it may be, that situation has been brewing for decades." - explaining that clinical dementia in one's 70s is the result of 20 to 40 years of silent metabolic dysfunction.
• At 0:07:06 - "90% of America's pre-diabetic patients don't know it. Cuz you get your annual blood work, you get a pat on the back, well, you're not diabetic yet, go home and hope for the best." - highlighting how standard medical care ignores the pre-diabetic state that drives Pre-Alzheimer's.
• At 0:08:49 - "If you live to be age 85, and I'm sure that's your plan, and I'm sure that's the plan of everybody watching us right now, your risk is 40 to 50%. That's basically a flip of a coin of becoming an Alzheimer's diagnosed individual or not." - illustrating the staggering lifetime prevalence of Alzheimer's in older age.
• At 0:13:16 - "Between three and five." - defining the optimal fasting insulin level (as opposed to standard lab reference ranges) when asked by Gary Brecka.
• At 0:16:04 - "And when those microglial cells become the evil twin, they destroy synapses. They cause lack of connection in the brain, loss of connectivity. They threaten the neurons and they destabilize the blood-brain barrier." - describing the pathological damage caused when microglia shift from their M2 state to their M1 state.
• At 0:16:20 - "That shift of those immune cells from being what we call M2 supportive, brain defenders, to being destructive is dictated by their metabolism, and their metabolism mirrors your body's metabolism." - defining the core concept of immunometabolism in the brain.
• At 0:17:20 - "We're spending, you know, 360 billion with a B on caring for Alzheimer's patients for a disease that I will tell you today is largely preventable." - contrasting the massive economic cost of Alzheimer's care with its high preventability through metabolic management.
• At 0:28:18 - "Or even those who decided to do both, and by far and away, the winner was both." - summarizing a 32-study meta-analysis showing that combining aerobic exercise and resistance training yields the best cognitive outcomes, especially in those 65+ or with existing impairment.
• At 0:37:18 - "When the shift happens, their mitochondrial function basically evaporates almost fully. Now they're using glycolysis, another energy-producing pathway, far less effective." - explaining the bioenergetic collapse inside M1 microglial cells.
• At 0:41:21 - "In these conditions like Alzheimer's, patients are not losing their memory per se, they're losing access to their memory." - clarifying how synaptic destruction and loss of connectivity impair memory retrieval.
• At 0:43:02 - "What they found is that in 70% of the individuals that underwent this intervention, their cognitive decline either stopped, which no drug can do, or improved. Their cognitive function improved." - detailing the results of the 20-week Tanzi and Ornish lifestyle intervention trial in 51 Alzheimer's patients.
• At 0:51:18 - "25% of people getting these IV drugs to rid their brains of beta-amyloid had brain hemorrhages, brain swelling, or died." - citing the severe adverse event rate found in the Cochrane review of 20,342 patients taking anti-amyloid monoclonal antibodies.
• At 0:51:55 - "The word used in the Cochrane analysis was the benefits were trivial." - emphasizing the lack of clinical efficacy of anti-amyloid drugs despite their 1-in-4 rate of severe complications.
• At 1:11:06 - "The new study in JAMA showed that this p-tau217, one of the fundamental blood tests I'd like everyone to get, is predictive of who's going to get it, well in advance." - recommending a specific blood biomarker that predicts Alzheimer's risk long before symptoms appear.
• At 1:34:10 - "Oxytocin is bound to the supportive microglial cell and tells them, you better just stay in this M2 configuration and be a brain defender." - explaining the biochemical mechanism by which social connection and eye contact protect the brain from neuroinflammation.

Takeaways

• Track and optimize "Pre-Alzheimer's" blood biomarkers early: Do not wait for a diabetes diagnosis or cognitive symptoms in your 70s. Request blood tests for fasting insulin (aim for an optimal range of 3 to 5), p-tau217 (to assess early predictive risk for Alzheimer's), A1C, fasting blood sugar, and Vitamin D (aim for an optimal range of 60 to 80, accounting for potential VDR genetic polymorphisms rather than settling for a standard lab "normal" of 30).
• Test and lower your homocysteine with the right B vitamins: Measure your blood homocysteine levels and aim to drive them down to ~6.8–7 (as Perlmutter and Brecka did). Use B-complex vitamins or TMG (trimethylglycine), and if you have an MTHFR genetic polymorphism, specifically supplement with methylated forms such as methylfolate and sublingual methyl-B12.
• Combine aerobic, resistance, and balance training: To maximize irisin, BDNF, and mitochondrial biogenesis while preventing sarcopenia, perform both aerobic exercise and resistance training—which a 32-study meta-analysis proved far superior to either modality alone—and incorporate flexibility and balance work to prevent falls and injuries as you age.
• Supplement with creatine monohydrate (and alert your doctor about creatinine): Consider taking creatine monohydrate (Perlmutter takes 7 grams daily) to support muscle mass and brain phosphocreatine reservoirs. If your blood work shows elevated creatinine, ensure your physician checks other kidney markers like BUN or eGFR so your supplementation or heavy lifting is not misdiagnosed as kidney failure.
• Eliminate all sugars and switch to safe sweeteners: Stop consuming cane sugar, coconut sugar, and organic sugar, and consider a ketogenic or plant-forward low-glycemic diet to restore insulin sensitivity. Avoid high consumption of erythritol (which is linked to cardiovascular risk and often mixed into monk fruit) and use allulose or pure monk fruit instead.
• Choose high-quality, non-oxidized Omega-3 (DHA) supplements: Support neuronal membranes and BDNF by taking DHA, but avoid cheap fish oil sold in clear plastic bottles that has become oxidized and rancid.
• Prioritize 8 hours of sleep for glymphatic clearance: Treat sleep as a non-negotiable metabolic and neurological therapy to clear misfolded proteins and keep microglia in their M2 state; if you suffer a single night of poor sleep, strategic morning caffeine can help offset acute next-day cognitive impairment.
• Eliminate systemic sources of inflammation: Protect your brain's microglia from polarizing cytokines by maintaining rigorous oral hygiene to prevent periodontal/gum disease, healing gut dysbiosis/leaky gut, and filtering indoor air to avoid inhaling PM 2.5 particles (such as from wildfire smoke).
• Cultivate daily eye-to-eye social connection and cognitive engagement: Combat cortisol-driven hippocampal shrinkage from social isolation by actively engaging in community, making eye contact with loved ones or a dog to trigger microglial-protecting oxytocin, and challenging your brain (such as with the BrainHQ app used in the POINTER study).